


AbbVie's Commitment to Immunology

Panama City | August 2026

Domenico Ruocco, MD, MSc.

Therapeutic Area Lead | Immunology



For 25 years, we've been a trusted leader in Immunology, dedicated to transforming patients' lives today and tomorrow.

►► **Our Vision is to eliminate the burden of disease for patients affected by immune-mediated conditions.**

AbbVie's Legacy in Immunology

abbvie



AbbVie Legacy By the Numbers

Leader in the field of immunology,
pursuing breakthrough science and
delivering **best-in-class medicines**

25

YEARS
IMMUNOLOGY
EXPERIENCE¹

19

IMMUNOLOGICAL
CONDITIONS
TREATED²⁻⁸

40+

IMMUNOLOGY MEDICINES
EVALUATED

725+

STUDIES EXPLORED
ACROSS IMMUNOLOGY

178+

COUNTRIES WHERE OUR
IMMUNOLOGY PRODUCTS
HELP PATIENTS

>1MM

IMMUNOLOGY PATIENTS
TREATED WORLDWIDE¹

Pioneering First Therapies

1st

- **Fully human monoclonal antibody** approved for therapeutic use⁹
- Approved medication available for **non-radiographic axSpA patients** (nr-axSpA) in Europe¹⁰
- **Biologic** treatment option approved for the treatment of **Hidradenitis Suppurativa** (HS) patients¹¹
- FDA-approved biologic proven to treat **non-infectious intermediate, posterior, and panuveitis** in adults and children 2 years of age and older¹²

AbbVie Developed and was First to Assess Many Disease Measures Across Immunology

Developed^a




Hidradenitis Suppurativa

- HiSCR¹⁴



Atopic Dermatitis

- ADerm-SS¹⁵
- ADerm-IS¹⁵



Ulcerative Colitis

- Abdominal pain¹⁶
- Nocturnal bowel movement¹⁶
- Tenesmus¹⁶
- Fecal incontinence¹⁶
- Sleep interruptions¹⁶
- Bowel urgency¹⁶
- UCSQ¹⁷



Crohn's Disease

- CSS¹⁸



Psoriatic Arthritis

- SAPS¹⁹

First to Assess^b




Rheumatoid Arthritis

- FACIT-F²⁰



Atopic Dermatitis

- MDA (achievement of)²¹



Ulcerative Colitis

- FACIT-F²²
- HEMR or deep mucosal healing^{23,c}



Crohn's Disease

- Endoscopic response^{24,25,d}
- FACIT-F²²
- PRO-2 (stool frequency / abdominal pain)²⁵

Addressing High Unmet Needs

abbvie



Addressing High Unmet Needs across Immune-Mediated Diseases¹

We strive to develop our transformational products to have a **positive contribution in underserved areas of disease** where we know we can have an impact on patient lives.



In dermatology we seek new solutions for **immune-mediated skin diseases**, especially those that are difficult to diagnose and treat.



In gastroenterology we explore innovative approaches for **inflammatory bowel disease** and **stomach and intestinal disorders**.



In rheumatology we're committed to transforming therapies for conditions affecting **joints, muscles, and ligaments**.

Products, Pipeline, and Science

abbvie



Our Products and Pipeline

Our expertise is built by breakthrough innovation, with the goal of providing a portfolio of **best-in-class medicines** that have a remarkable impact on patients' lives

3

IN MARKET
IMMUNOLOGY PRODUCTS²⁻⁷

24

Pipeline Indications²⁶

35+

IMMUNOLOGICAL
CONDITIONS STUDIED

70+

COUNTRIES WHERE ABBVIE IS
RUNNING IMMUNOLOGY
CLINICAL TRIALS

20+

COMPOUNDS
IN DISCOVERY²⁷

555+

CURRENTLY ACTIVE
IIS, PHASE 3, and 4 TRIALS
IN IMMUNOLOGY

AbbVie Has Provided Treatments In 19 Immune-Mediated Diseases, Including 7 Pediatric Conditions²⁻⁸

DERMATOLOGY

PsA: Psoriatic Arthritis

PsO: Plaque Psoriasis

PedPs: Pediatric Plaque Psoriasis (ages 4-17)

HS: Hidradenitis Suppurativa

AdolHS: Adolescent Hidradenitis Suppurativa (ages 12-17)

AD: Atopic Dermatitis

GASTROENTEROLOGY


CD: Crohn's Disease

PedCD: Pediatric Crohn's Disease (ages 6-17)

UC: Ulcerative Colitis

PedUC: Pediatric Ulcerative Colitis (ages 5-17)

Intestinal BD: Intestinal Behçet's Disease



RHEUMATOLOGY

PsA: Psoriatic Arthritis

P-JIA: Polyarticular Juvenile Idiopathic Arthritis (ages 2-17)

ERA: Enthesitis-related Arthritis (ages 6-17)

Nr-axSpA: Non-radiographic Axial Spondyloarthritis

AS: Ankylosing Spondylitis

RA: Rheumatoid Arthritis

GCA: Giant Cell Arteritis

Uv: Noninfectious Intermediate, Posterior, and Panuveitis

PedUv: Pediatric Chronic Noninfectious Anterior Uveitis (ages 2-17)

Comprehensive Immunology Pipeline

AbbVie's products in development across Immunology.²⁶

To become a clinical trial investigator / investigative site on an AbbVie trial, submit your interest here: investigatorinquiry.abbvie.net.

Marketed and Late-Stage Immunology Portfolio (updated February 2026)																	
MOLECULE	POTENTIAL INDICATION	PHASE (1, 2, 3, SUBMITTED)				MOLECULE	POTENTIAL INDICATION	PHASE (1, 2, 3, SUBMITTED)				MOLECULE	POTENTIAL INDICATION	PHASE (1, 2, 3, SUBMITTED)			
RINVOQ® (upadacitinib) JAK1 selective inhibitor	Alopecia Areata	■	■	■	■	ABBV-319 CD19 targeting antibody drug conjugate	Sjogern's disease	■	■	■		ABBV-142 anti- LPAR1 antibody	Idiopathic Pulmonary Fibrosis	■	■	■	
	Ankylosing Spondylitis	---Approved---					Systemic Lupus Erythematosus (SLE)	■	■	■		ABBV-619 CD19 CAR-T therapy	Autoimmune diseases	■	■	■	
	Atopic Dermatitis	---Approved---				ABBV-8736 anti-TREM1 antibody	Crohn's Disease	■	■	■		ABBV-141 anti-LPAR1 antibody	Idiopathic Pulmonary Fibrosis	■	■	■	
	Axial SpA	---Approved---				ABBV-243 Integrin β7 (α4β7 and αEβ7)	Inflammatory Bowel Disease (IBD)	■	■	■		Lutikizumab IL-1α/1β antagonist	Hidradenitis Suppurativa	■	■	■	
	Crohn's Disease	---Approved---											Ulcerative Colitis	■	■	■	
	Giant Cell Arteritis (GCA)	---Approved---											Atopic Dermatitis	■	■	■	
	Hidradenitis Suppurativa	■	■	■		ABBV-547 anti-IL-23 antibody	Psoriasis	■	■	■		ABBV-722 anti-LPAR1 antibody	Idiopathic Pulmonary Fibrosis	■	■	■	
	Psoriatic Arthritis	---Approved---				Lutikizumab + Ravagalimab IL-1α/1β antagonist + CD40 antagonist	Rheumatoid Arthritis	■	■	■			Systemic Sclerosis	■	■	■	
	Rheumatoid Arthritis	---Approved---										SKYRIZI® (risankizumab) + ABBV-382 anti-IL-23 antibody + anti-a4b7 mAb	Crohn's Disease	■	■	■	
	Systemic Lupus Erythematosus (SLE)	■	■	■		SKYRIZI® (risankizumab) + Lutikizumab anti-IL-23 antibody + IL-1α/1β antagonist	Crohn's Disease	■	■	■							
	Takayasu Arteritis	■	■	■		Psoriatic Arthritis	■	■	■								
	Ulcerative Colitis	---Approved---															
Vitiligo	■	■	■	■													

---Approved--- Currently approved in US and EU; Indications in dermatology, gastroenterology, and rheumatology.

AbbVie in no way intends to recommend or imply that the products should be used for unapproved uses, or that the FDA, European Commission or any other health authorities have deemed investigational therapies safe and/or effective.

Pipeline Updated February 4, 2026. Accessed February 19, 2026.

Thank you!

